Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
SRTS 
Sensus Healthcare Inc (SRTS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: SRTS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $7.5
1 Year Target Price $7.5
| 2 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -33.39% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 54.42M USD | Price to earnings Ratio - | 1Y Target Price 7.5 |
Price to earnings Ratio - | 1Y Target Price 7.5 | ||
Volume (30-day avg) 5 | Beta 1.39 | 52 Weeks Range 3.03 - 9.33 | Updated Date 10/17/2025 |
52 Weeks Range 3.03 - 9.33 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.05 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -2.26% | Operating Margin (TTM) 40.84% |
Management Effectiveness
Return on Assets (TTM) -1.46% | Return on Equity (TTM) -1.62% |
Valuation
Trailing PE - | Forward PE 21.37 | Enterprise Value 32849519 | Price to Sales(TTM) 1.45 |
Enterprise Value 32849519 | Price to Sales(TTM) 1.45 | ||
Enterprise Value to Revenue 0.87 | Enterprise Value to EBITDA 8.68 | Shares Outstanding 16440036 | Shares Floating 13856979 |
Shares Outstanding 16440036 | Shares Floating 13856979 | ||
Percent Insiders 16.98 | Percent Institutions 29.55 |
Upturn AI SWOT
Sensus Healthcare Inc
Company Overview
History and Background
Sensus Healthcare, Inc. was founded in 2010 and is headquartered in Boca Raton, Florida. It specializes in developing and marketing superficial radiation therapy (SRT) devices for treating non-melanoma skin cancers and keloids.
Core Business Areas
- Superficial Radiation Therapy (SRT) Systems: Sensus Healthcare's primary business revolves around developing and selling SRT systems, notably the SRT-100 product line. These systems are used by dermatologists, radiation oncologists, and other healthcare professionals to treat skin conditions without the need for surgical intervention.
- Treatment Services: Sensus Healthcare also provides treatment services using its SRT systems, either directly or through partnerships with healthcare providers. This includes training and support for using the devices.
- After-Sales Support and Accessories: The company also generates revenue through after-sales support, including maintenance and service contracts, as well as through the sale of accessories related to the SRT systems.
Leadership and Structure
Joe Sardano serves as the Chairman and CEO. The company operates with departments including sales, marketing, research & development, regulatory affairs, and finance.
Top Products and Market Share
Key Offerings
- SRT-100 Vision: The SRT-100 Vision is Sensus Healthcare's flagship product. It uses low-energy X-rays to treat non-melanoma skin cancers and keloids. Market share data is proprietary, but it is a significant player in the superficial radiation therapy market. Competitors include companies offering alternative therapies such as surgical excision, cryotherapy, and topical treatments.
- SRT-100: The SRT-100 is the predecessor to the Vision, offering similar capabilities but with different features. Market share data is proprietary. Competitors include companies offering alternative therapies such as surgical excision, cryotherapy, and topical treatments.
Market Dynamics
Industry Overview
The market for non-melanoma skin cancer treatment is growing due to increased awareness, aging populations, and improved diagnostic methods. The demand for non-invasive treatment options is also increasing.
Positioning
Sensus Healthcare is positioned as a provider of non-invasive SRT solutions, targeting dermatologists and radiation oncologists. The company's competitive advantage lies in its specialized SRT technology and focus on aesthetic outcomes.
Total Addressable Market (TAM)
The global market for non-melanoma skin cancer treatment is estimated to be in the billions of dollars annually. Sensus Healthcare is positioned to capture a portion of this market through its SRT technology. Estimated at 10B+ globally with future expectations of rising to 12-15B.
Upturn SWOT Analysis
Strengths
- Specialized SRT technology
- Focus on non-invasive treatment
- Established presence in dermatology and radiation oncology
- Strong intellectual property portfolio
Weaknesses
- Reliance on a single product line
- Limited geographic diversification
- Dependence on regulatory approvals
- Relatively small company size
Opportunities
- Expanding into new geographic markets
- Developing new applications for SRT technology
- Partnering with larger healthcare companies
- Increasing adoption of non-invasive treatments
Threats
- Competition from alternative treatments
- Changes in reimbursement policies
- Technological advancements by competitors
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- INTU
- VAR
- ELEK
Competitive Landscape
Sensus Healthcare competes with companies offering alternative treatments for non-melanoma skin cancer and keloids. The company's advantage lies in its specialized SRT technology, but it faces competition from larger, more established players.
Growth Trajectory and Initiatives
Historical Growth: Sensus Healthcare's growth has been driven by the adoption of its SRT systems. Historical growth rates depend on the sales of new and existing SRT-100 devices and market penetration.
Future Projections: Future growth depends on factors such as the company's ability to expand into new markets, develop new products, and gain regulatory approvals. Analyst estimates require access to real-time financial data.
Recent Initiatives: Recent initiatives may include product launches, partnerships, and regulatory filings.
Summary
Sensus Healthcare is a specialized medical device company with a focus on non-invasive skin cancer treatment. The company's SRT technology offers a unique value proposition, but it faces competition and relies heavily on a single product line. Expanding into new markets and developing new applications for its technology will be critical for future growth. The company's relatively small size presents both opportunities and risks.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Financial News Sources
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It should not be considered investment advice. Market share estimates are approximate. Financial data requires real-time feeds for accurate updates.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sensus Healthcare Inc
Exchange NASDAQ | Headquaters Boca Raton, FL, United States | ||
IPO Launch date 2016-06-03 | Co-Founder, Chairman & CEO Mr. Joseph C. Sardano | ||
Sector Healthcare | Industry Medical Devices | Full time employees 54 | Website https://sensushealthcare.com |
Full time employees 54 | Website https://sensushealthcare.com | ||
Sensus Healthcare, Inc. operates as a medical device company that manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sentinel service program, which offers its customers protection for their systems; and Transdermal Infusion system, a biophysical alternative to infuse high weight molecule modalities into the dermis for medical and aesthetic purposes without the use of needles. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Further, the company distributes laser devices, such as applications for hair removal, vascular lesions, acne treatment, skin toning, and skin rejuvenation, as well as epidermal pigment removal for spots, freckles, and tattoos. It markets its products primarily to private dermatology practices, and radiation oncologists in both private and hospital settings. The company was incorporated in 2010 and is based in Boca Raton, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.